Erschienen in:
01.04.2007 | Correspondence
Etanercept for the Management of Oral Lichen Planus
verfasst von:
Noam Yarom
Erschienen in:
American Journal of Clinical Dermatology
|
Ausgabe 2/2007
Einloggen, um Zugang zu erhalten
Excerpt
Oral lichen planus, a cell-mediated immune condition of unknown etiology, affects the oral mucosa in approximately 1–2% of the general population.[
1] Although many patients with oral lichen planus are asymptomatic and require no therapy, the management of patients who demonstrate atrophic and erosive lesions is a challenge for the clinician. Treatment modalities include topical, intralesional, or systemic corticosteroids, retinoids, azathioprine, and cyclosporine (ciclosporin). …